Lexaria Bioscience Corp. reported its third quarter 2025 financial results on July 16, 2025. The company announced revenue of US$174.0 thousand, representing a 107% increase from the third quarter of the prior year.
Despite the revenue growth, the net loss attributable to shareholders for the nine months ended May 31, 2025, widened significantly to US$9.21 million. This compares to a net loss of US$3.62 million in the prior year period.
The substantial increase in net loss is primarily due to a surge in operating expenses, which rose by $4.96 million year-over-year to $9.72 million for the nine-month period. This reflects intensified research and development activities, including the manufacturing of investigational drug products and the conduct of the Australian Phase 1b clinical trial.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.